Print Friendly, PDF & Email


AGE-4 Methylglyoxal modifiied

Catalogue number: AGE4-010

Clone14B5
IsotypeIgG
Units10 µg
HostMouse
Application ELISA
Western Blotting

Background
AGE-4 (Methylglyoxal-modified protein) has synergistic effects to TNF and TNF-induced apoptosis in different cell lines. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. AGE-4 (Methylglyoxal-modified proteins); in Western Blot no cross-reaction with glucose-modified AGEs (AGE-1), AGE-2 (Glycerolaldehyde-modified), AGE-3 (Glycolaldehyde-modified), AGE-5 (Glyoxal-modified), AGE-6 (3-DG-modified), CEL-BSA, CML-BSA and BSA.

Source

Immunogen: Methylglyoxal-modified BSA

Product
Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative

Purification Method: Protein G affinity purified monoclonal antibody in PBS with 2% Block Ace as stabilizer and 0.1% Proclin as preservative

Concentration: 0.25 mg/ml

Secondary Reagents: As secondary system in ELISA and Western Blot we recommend biotinylated anti-mouse IgG antibody (Art. No. ZU102) in combination with streptavidin-HRPO conjugate (Art. No. ZU054) or streptavidin-alkaline phosphatase (Art. No. ZU051).

Specificity

Species Reactivity: Human

Applications
ELISA, WB

Incubation Time: 60 min at RT or 18 hr at 2-8°C

Working Concentration: (liquid conc.) 0,1 µg/ml (WB) and 0,05 µg/ml (ELISA)

Positive Control: human lens, arteriosclerotic plaques

Storage
-20°C

Caution
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.

References
1. Takeuchi M. , Makita Z., Bucala R., Suzuki T., Koike T., and Kameda Y. (2000) Immunological evidence that non-carboxymethyllysine Advanced Glycation End-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6; 114-125. 2. Takeuchi M., Yanase Y., Matsuura N., Yamagishi S., Kameda Y., Bucala R., and Z. Matika (2001) Immunological detection of a novel Advanced Glycation End-Product. Mol. Med. 7; 783-791. 3. Van Herreweghe F. et al. (2002) Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE.: Proc .Natl. Acad. Sci. U S A.;99(2):949-954. 4. Speer O. et al.(2003) Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification. J. Biol .Chem. 278(37):34757-63.


AGE-4 Methylglyoxal modifiied

$1,080.00

SKU: AGE4-010 Categories: ,

Brand

Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370
Email: info@exalpha.com

Member

Newsletter